Investment Rating - The investment rating for the company is "Positive" [2] Core Insights - The company reported a revenue of $10.14 billion for Q2 2025, representing a year-on-year increase of 7.1%, with a gross margin of 68.3%, up by 4.1 percentage points [2] - Revenue from new tobacco products reached $4.16 billion, showing a year-on-year growth of 15.2%, accounting for 41% of total revenue, with a gross margin of 69.0%, an increase of 4.6 percentage points [2] - The new tobacco segment is viewed as the company's second growth curve, with continuous expansion in product and regional matrices, now available in 97 markets globally, with a total user base of 41.5 million, an increase of 5 million year-on-year [2] - The core product, IQOS, achieved a shipment volume of 39.9 billion units in Q2, a year-on-year increase of 9.2%, with revenue exceeding $3 billion and a market share of 76% in the HNB market [2][3] - The company anticipates a decline of 2% in global cigarette sales for 2025, while maintaining a growth forecast of 12% to 14% for new tobacco products, with HNB growth expected at 10% to 12% [3] Summary by Sections Financial Performance - Q2 2025 revenue was $10.14 billion, up 7.1% year-on-year, with a gross margin of 68.3% [2] - New tobacco revenue was $4.16 billion, a 15.2% increase, with a gross margin of 69.0% [2] Product Performance - IQOS shipments reached 39.9 billion units, a 9.2% increase, with revenue over $3 billion [2][3] - The nicotine pouch segment saw a 23.8% increase in sales, driven by the ZYN brand in the U.S. [3] - VEEV sales doubled in Q2 2025, primarily due to European market contributions [3] Market Outlook - The company expects a 2% decline in cigarette sales for 2025, while new tobacco products are projected to grow by 12% to 14% [3] - The introduction of IQOS ILUMA in the U.S. is anticipated to be a significant change in the new tobacco industry [3]